Amyris Inc. [NASDAQ: AMRS] gained 0.68% or 0.01 points to close at $1.47 with a heavy trading volume of 3959507 shares. The company report on January 4, 2023 that AMYRIS TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE.
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform today announced that management will present at the 41st Annual J.P. Morgan Health Care Conference on Wednesday, January 11, 2023, at 11:15 am PT (2:15 pm ET) in San Francisco.
A live webcast of the presentation and a replay will be available on the Investor Relations section of the company’s website at https://investors.amyris.com/events-and-presentations.
It opened the trading session at $1.45, the shares rose to $1.52 and dropped to $1.37, the range by which the price of stock traded the whole day. The daily chart for AMRS points out that the company has recorded -27.94% loss over the past six months. However, it is still -17.6% lower than its most recent low trading price.
If we look at the average trading volume of 6.33M shares, AMRS reached to a volume of 3959507 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Amyris Inc. [AMRS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMRS shares is $7.02 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMRS stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Amyris Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 10, 2022. The new note on the price target was released on November 09, 2022, representing the official price target for Amyris Inc. stock. Previously, the target price had yet another drop from $4 to $2, while ROTH Capital kept a Neutral rating on AMRS stock.
The Average True Range (ATR) for Amyris Inc. is set at 0.20, with the Price to Sales ratio for AMRS stock in the period of the last 12 months amounting to 2.06.
Trading performance analysis for AMRS stock
Amyris Inc. [AMRS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.38. With this latest performance, AMRS shares dropped by -15.52% in over the last four-week period, additionally sinking by -27.94% over the last 6 months – not to mention a drop of -67.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMRS stock in for the last two-week period is set at 39.28, with the RSI for the last a single of trading hit 37.20, and the three-weeks RSI is set at 40.74 for Amyris Inc. [AMRS]. The present Moving Average for the last 50 days of trading for this stock 1.9697, while it was recorded at 1.4340 for the last single week of trading, and 2.6408 for the last 200 days.
Amyris Inc. [AMRS]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Amyris Inc. [AMRS] shares currently have an operating margin of -48.31 and a Gross Margin at +51.77. Amyris Inc.’s Net Margin is presently recorded at -79.12.
Return on Equity for this stock declined to -679.38, with Return on Assets sitting at -45.95.
Amyris Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.50 and a Current Ratio set at 0.90.
Amyris Inc. [AMRS]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AMRS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amyris Inc. go to 30.00%.
An analysis of insider ownership at Amyris Inc. [AMRS]
There are presently around $172 million, or 38.90% of AMRS stock, in the hands of institutional investors. The top three institutional holders of AMRS stocks are: VANGUARD GROUP INC with ownership of 19,793,472, which is approximately 3.737% of the company’s market cap and around 0.70% of the total institutional ownership; BLACKROCK INC., holding 13,269,048 shares of the stock with an approximate value of $19.51 million in AMRS stocks shares; and VIVO CAPITAL, LLC, currently with $11.39 million in AMRS stock with ownership of nearly -33.425% of the company’s market capitalization.
Positions in Amyris Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 102 institutional holders increased their position in Amyris Inc. [NASDAQ:AMRS] by around 11,385,607 shares. Additionally, 87 investors decreased positions by around 32,789,334 shares, while 48 investors held positions by with 72,835,431 shares. The mentioned changes placed institutional holdings at 117,010,372 shares, according to the latest SEC report filing. AMRS stock had 25 new institutional investments in for a total of 1,853,173 shares, while 35 institutional investors sold positions of 10,506,565 shares during the same period.